As Women’s History Month continues, pharmaphorum web editor Nicole Raleigh welcomed a group of expert individuals onto the podcast to discuss not just the inequalities in women’s health, bu
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in th
Clinical research continues to struggle with a lack of representation within trial populations, and gender diversity in clinical trials remains a critical issue.
Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.